Scientific Opinion on the substantiation of a health claim related to β‐galactosidase from Kluyveromyces lactis in Colief® and a reduction of gastrointestinal discomfort pursuant to Article 14 of Regulation (EC) No 1924/2006

Scientific Opinion on the substantiation of a health claim related to β‐galactosidase from Kluyveromyces lactis in Colief® and a reduction of gastrointestinal discomfort pursuant to Article 14 of Regulation (EC) No 1924/2006

Abstract Following an application from Cross Vetpharm Group UK Ltd, submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the United Kingdom, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to...

Full description

Bibliographic Details
Main Author: EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
Format: Article
Language:English
Published: Wiley 2015-07-01
Series:EFSA Journal
Subjects:
β galactosidase
Kluyveromyces lactis
gastrointestinal discomfort
children
health claims
Online Access:https://doi.org/10.2903/j.efsa.2015.4187

Internet

https://doi.org/10.2903/j.efsa.2015.4187

Similar Items